July 31, 2017 — Accuray Inc. announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its iDMS Data Management System, enabling its use with the company's TomoTherapy platform. It is designed to integrate with a wide range of technologies, including the Radixact, TomoTherapy and CyberKnife systems, Accuray Precision Treatment Planning System, and third-party treatment planning and oncology information systems.
The iDMS System is a centralized database that shares and makes data accessible between multiple Accuray radiotherapy treatment delivery systems, adding flexibility and improving efficiency in the radiation therapy department. It provides an integrated platform for storing and managing all patient and treatment plan data, allowing clinicians to securely and seamlessly access the data they need to drive efficient, informed, effective radiation treatments.
For more information: www.accuray.com
April 10, 2026 
